RET and non-small cell lung carcinoma: ,17 Nevertheless, in early-phase clinical trials, novel selective RET inhibitors, such as LOXO-292 (selpercatinib) and BLU-667 (pralsetinib) revealed objective response rates of 61%18 and 64%,19 respectively, in pretreated patients with NSCLC, and of 84%18 and 72%,19 respectively, in patients who were treatment-naive.